Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer - OncLive

OncLive
Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer
OncLive
The combination of neratinib (Nerlynx) and T-DM1 (ado-trastuzumab emtansine; Kadcyla) induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer, according to results from the phase Ib NSABP FB-10 ...